Suppr超能文献

年龄和显性蛋白尿对转诊队列中 3 至 5 期慢性肾脏病结局的影响。

Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort.

机构信息

Department of Nephrology, Rinku General Medical Center, Izumisano 598-8577, Japan.

出版信息

Clin J Am Soc Nephrol. 2010 Sep;5(9):1558-65. doi: 10.2215/CJN.08061109. Epub 2010 Jun 17.

Abstract

BACKGROUND AND OBJECTIVES

Population-based studies have reported outcomes and risk factors for patients with chronic kidney disease (CKD), defined primarily by decreased estimated GFR (eGFR). They are characterized by old age, low proteinuria level, and stage 3 CKD. However, many patients referred to nephrologists are younger and have overt proteinuria and advanced CKD. This study evaluated the association between outcomes and those factors among referred CKD patients.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We retrospectively reviewed 461 referred patients with stage 3 to 5 CKD from January 2003 to December 2007. Key outcomes were death and ESRD. Patients were followed from the time of first serum creatinine measurement to December 2009.

RESULTS

The median age of subjects was 67.0 years, and median follow-up was 3.2 years. Overt proteinuria was present in 57.0% of subjects. For stage 3, 4, and 5 CKD, cumulative mortality and probability of ESRD at 3 years was 9.5 and 6.5%, 11.2 and 27.8%, and 16.5 and 79.1%, respectively. Using proportional-hazards regression models, age was a determinant for death, whereas overt proteinuria was strongly associated with ESRD. Among stage 3 CKD patients older than 65 years without overt proteinuria, the incidence of death before renal replacement therapy (RRT) was 2.8/100 patient-years and none had ESRD. In patients with advanced CKD and overt proteinuria, the incidence of ESRD was substantially higher than that of death before RRT.

CONCLUSIONS

Stratification by age, proteinuria level, and CKD stage could predict the competing outcomes of death before RRT and ESRD among CKD patients.

摘要

背景与目的

基于人群的研究报告了慢性肾脏病(CKD)患者的结局和风险因素,这些患者主要通过估算肾小球滤过率(eGFR)降低来定义。他们的特点是年龄较大、蛋白尿水平较低且处于 CKD 第 3 期。然而,许多转介给肾病学家的患者年龄较轻,且存在显性蛋白尿和晚期 CKD。本研究评估了转介 CKD 患者的结局与这些因素之间的关联。

设计、地点、参与者和测量方法:我们回顾性分析了 2003 年 1 月至 2007 年 12 月期间的 461 例 3 至 5 期 CKD 患者。主要结局为死亡和终末期肾病(ESRD)。患者从首次血清肌酐测量时间开始随访至 2009 年 12 月。

结果

受试者的中位年龄为 67.0 岁,中位随访时间为 3.2 年。57.0%的患者存在显性蛋白尿。对于 CKD 第 3、4 和 5 期,3 年时的累积死亡率和 ESRD 概率分别为 9.5%和 6.5%、11.2%和 27.8%、16.5%和 79.1%。使用比例风险回归模型,年龄是死亡的决定因素,而显性蛋白尿与 ESRD 密切相关。在年龄大于 65 岁且无显性蛋白尿的 CKD 第 3 期患者中,在接受肾脏替代治疗(RRT)之前死亡的发生率为 2.8/100 患者年,且无人发生 ESRD。在晚期 CKD 且存在显性蛋白尿的患者中,ESRD 的发生率远高于 RRT 之前的死亡率。

结论

按年龄、蛋白尿水平和 CKD 分期分层可以预测 CKD 患者 RRT 前死亡和 ESRD 的竞争结局。

相似文献

引用本文的文献

2
Treatment of chronic kidney disease in older populations.老年人群慢性肾脏病的治疗。
Nat Rev Nephrol. 2024 Sep;20(9):586-602. doi: 10.1038/s41581-024-00854-w. Epub 2024 Jul 8.
5
Insights into Cognitive Brain Health in Chronic Kidney Disease.慢性肾脏病认知脑健康的见解
Gerontol Geriatr. 2022;8(2). doi: 10.26420/gerontolgeriatrres.2022.1074. Epub 2022 Aug 5.
9
Aging and Renal Disease: Old Questions for New Challenges.衰老与肾脏疾病:应对新挑战的旧问题
Aging Dis. 2021 Apr 1;12(2):515-528. doi: 10.14336/AD.2020.0703. eCollection 2021 Apr.

本文引用的文献

2
Prevalence of chronic kidney disease in the Japanese general population.日本一般人群中慢性肾脏病的患病率。
Clin Exp Nephrol. 2009 Dec;13(6):621-30. doi: 10.1007/s10157-009-0199-x. Epub 2009 Jun 11.
3
Prediction, progression, and outcomes of chronic kidney disease in older adults.老年人慢性肾脏病的预测、进展及预后
J Am Soc Nephrol. 2009 Jun;20(6):1199-209. doi: 10.1681/ASN.2008080860. Epub 2009 May 21.
8
Revised equations for estimated GFR from serum creatinine in Japan.日本基于血清肌酐估算肾小球滤过率的修订方程。
Am J Kidney Dis. 2009 Jun;53(6):982-92. doi: 10.1053/j.ajkd.2008.12.034. Epub 2009 Apr 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验